Fig. 1 · Structure

Documents & Downloads

JNJ-7706621

Cat. No. A10494 CAS 443797-96-4

CDK/Aurora A/B Inhibitor

JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.

In Stock

Publications for JNJ-7706621

1 publication citing this product

  1. Yuta Tanizaki, .et al. , Commun Biol, 2022, 5: 112 PMID: 35132135

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In a cell-free Aurora A conformational assay, JNJ-7706621 favored the DFG-in state, with the smallest shift among the 14 DFG-in-inducing compounds tested. This binding-associated conformational response is distinct from a catalytic IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CDK6/cyclinD1 IC50 175 nM
CDK2/cyclinE IC50 3 nM
Cdk4/cyclin D1 IC50 253 nM
Cdk1/cyclin B IC50 9 nM
cdk2/cyclin A IC50 4 nM
CDK3/Cyclin E IC50 58 nM
Aurora A IC50 11 nM
Aurora B IC50 15 nM
VEGF-R2 IC50 154 nM
VEGF-R1 IC50 6400 nM
VEGF-R3 IC50 735 nM
FGF-R1 IC50 575 nM
FGF-R2 IC50 226 nM
GSK3β IC50 254 nM

14 targets · Scroll to view more

JNJ-7706621 Research Summary

This section summarizes 2 in vitro studies of JNJ-7706621 from 2 published references. In vitro models include NCI-A549 human lung cancer cells.

JNJ-7706621 In Vitro Studies

In NCI-A549 cells, JNJ-7706621 (10 μM, 10 h) reduced ERK1/2 protein abundance without reducing ERK1/2 mRNA. MG132 cotreatment counteracted the protein decrease, supporting proteasome-dependent regulation in this model. The experiment does not establish CDK2-selective drug action. [2]

Aurora A conformational response to inhibitor binding

Biochemical assay · Fluorescently labeled human Aurora A protein, including unphosphorylated and phosphorylated states [1]

JNJ-7706621 weakly favored the DFG-in state in the inhibitor panel. This measures conformational response to binding rather than catalytic inhibition potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Direction and relative magnitude of Aurora A conformational changeQualitative response Weakest DFG-in inducer among the 14 DFG-in-inducing compounds profiled[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 nM to 5 μM inhibitor titration; 50 nM FRET sensor
Method
Cell-free TR-FRET in 384-well plates
Vehicle
DMSO baseline shown in Fig. 3B; final solvent percentage not established from retrieved main text
Reported limits
Incubation duration and compound vendor/lot details were not established from the retrieved main text. SI was not retrieved. No IC50 or exact distance was extracted.
Methods and source locations

Compound reported in the paper: JNJ-7706621

Evidence for the named compound in the reported assay; no salt conversion or validation of the catalog lot.

Fig. 3A–D and caption; Results: Type I Inhibitors Stabilize the DFG-In State by Promoting Active Site Closure; Materials and Methods: FRET sensor, TR-FRET assay and data fitting

Direction and relative magnitude of Aurora A conformational change: Time-resolved FRET; activation-loop distance fitting; apo/DMSO baseline; donor-only and donor-plus-acceptor controls. Fig. 3A reports fitted values with 95% confidence intervals. — Fig. 3A–D and caption; Results: Type I Inhibitors Stabilize the DFG-In State by Promoting Active Site Closure; Materials and Methods: FRET sensor, TR-FRET assay and data fitting

ERK1/2 protein response with proteasome and transcript controls

Cell-based study · NCI-A549 human lung cancer cells [2]

JNJ-7706621 lowered ERK1/2 protein abundance; cotreatment with MG132 counteracted the decrease. ERK1/2 mRNA levels were not reduced. These findings support a post-transcriptional response in this model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ERK1/2 protein abundance normalized to GAPDHQualitative response Decreased with JNJ-7706621; decrease counteracted by MG132 cotreatment[2]
ERK1 and ERK2 transcript abundanceQualitative response No reduction reported after JNJ-7706621 treatment[2]

Literature-Reported Treatment Conditions

Treatment concentration
JNJ-7706621: 10 μM; MG132 cotreatment: 30 μM
Exposure duration
10 h before harvest
Method
Cell treatment followed by immunoblotting and qRT-PCR
Co-treatment
Separate cotreatment arm with MG132; JNJ-7706621 alone also evaluated
Reported limits
Final solvent composition for Fig. 2A/D is not specified in the reviewed caption or shared drug methods. No numerical fold change or IC50 was inferred from the graph.
Methods and source locations

Compound reported in the paper: JNJ-7706621

Evidence for the named compound in the reported assay; no salt conversion or validation of the catalog lot.

Fig. 2A, B, D and caption; Results: CDK2 regulates ERK1/2 protein level; Materials and methods: cell culture, reagents/antibodies, RNA extraction and real-time PCR, Western blotting

ERK1/2 protein abundance normalized to GAPDH: Western blot and ImageJ quantification; untreated control, JNJ-7706621 alone, and JNJ-7706621 plus MG132; means ± SD, at least three independent experiments — Fig. 2A–B and caption

ERK1 and ERK2 transcript abundance: qRT-PCR of remaining cells from Fig. 2A, normalized to β-actin; means ± SD of three independent experiments — Fig. 2D and caption; Results: CDK2 regulates ERK1/2 protein level

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 443797-96-4
Applications CDK/Aurora A/B Inhibitor
Formula C15H12F2N6O3S
Molecular Weight 394.4
SMILES
C1=CC(=C(C(=C1)F)C(=O)N2C(=NC(=N2)NC3=CC=C(C=C3)S(=O)(=O)N)N)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 67 mg/mL (169.89 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
13 mg/mL
Vehicle
0.5% methylcellulose+0.2% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

JNJ-7706621 Research References

  1. [1] Lake EW, Muretta JM, Thompson AR, et al. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states. Proceedings of the National Academy of Sciences of the United States of America (2018). PMID: 30518564 DOI: 10.1073/pnas.1811158115 Source material
  2. [2] Wu J, Chen Y, Li R, et al. Synergistic anticancer effect by targeting CDK2 and EGFR-ERK signaling. The Journal of cell biology (2024). PMID: 37955924 DOI: 10.1083/jcb.202203005 Source material

Publications

1 publication citing this product

  1. Yuta Tanizaki, .et al. , Commun Biol, 2022, 5: 112 PMID: 35132135

Added to your cart

View Cart Checkout
Loading...